In 2023, there were around ** deaths from Parkinson's disease per 100,000 population in the state of Nebraska, the highest rate of death from Parkinson's disease among all U.S. states. This statistic presents the death rate from Parkinson's disease in the U.S. in 2023, by state.

In 2022, there were 4,289 deaths from Parkinson's disease in the state of California, the highest number of any state. This statistic presents the number of Parkinson's disease deaths in the U.S. in 2022, by state.

This dataset presents information on age-standardized incidence rates of Parkinson's disease for Alberta and selected geographies, expressed as per 100,000 population.

This dataset presents information on age-sex specific incidence rates of Parkinson's disease for Alberta, expressed as per 100,000 population.

This statistic shows the projected worldwide increase in the prevalence of Parkinson’s disease in 2005 and 2030. It is estimated, that the number of Parkinson's disease patients will increase from *** million in 2005 to *** million in 2030.

The death rate from Parkinson’s disease has gradually increased over the last decade. Parkinson’s disease is a nervous system disorder that progressively impacts movement. Symptoms include tremors, slowed movement, rigid muscles, speech changes and the loss of automatic movements. These symptoms start mildly but become more severe as the disease progresses. Parkinson’s disease death Parkinson’s disease is usually not considered a deadly disease, and many people with the disease have relatively normal life expectancies. Death from Parkinson’s disease results from complications arising from advanced symptoms, such as problems swallowing or falls. Therefore, the death rate from Parkinson’s disease increases significantly with age. Living with Parkinson’s disease It is predicted that by the year 2030 there will be around *** million people living with Parkinson’s disease in the United States. A survey of Parkinson’s disease patients showed that some of the most common symptoms from the disease included fatigue, tremors or shaking, trouble sleeping, and changes in handwriting. Common cognitive changes involved concentration and attention span, verbal fluency, information processing, and memory.

This statistic shows the projected number of people in the U.S. with Parkinson's disease in 2020 and 2030. In 2020, there are expected to be around 930,000 people with Parkinson's disease. This number is expected to reach over one million by the year 2030.

BackgroundThe pathogenesis of Parkinson’s disease (PD) remains incompletely understood, has drawn significant attention within the scope of the Global Burden of Disease (GBD) study. Therefore, to explore PD’s global burden and devise countermeasures is indispensable.MethodsData from GBD 2021 to analyze age standardized incidence rate (ASIR), prevalence rate (ASPR), mortality rate (ASMR), and disability adjusted life years (DALYs) rate (ASDR) burden of PD globally. Moreover, the estimated annual percentage change (EAPC) was utilized to gauge PD burden trends from 1990 to 2021. Subsequently, PD burden by sex and 21 GBD regions was further evaluated in 2021. Moreover, the influence of age, sex, and socio-demographic index (SDI) on burden of PD from 1990 to 2021 was examined. Finally, the projection of burden of PD from 2022 to 2026 was also conducted.ResultsFrom 1990 to 2021, ASIR, ASPR, and ASDR were shown to be on an upward trend for both males and females. However, ASMR was higher in males than in females. In addition, ASIR, ASPR, and ASDR in the East Asian region were found to be the highest, and they were higher among males than among females. Notably, with the elapse of years, PD’s total incidence cases, prevalence cases, mortality cases, and DALYs cases were all presented with an upward trend. Moreover, in 1990 and 2021, ASDR in 75–79 age group was the highest. Finally, from 2022 to 2026, PD’s ASIR and ASPR were predicted to exhibit an upward tendency, while ASMR and ASDR were expected to show a downward trend.ConclusionThe research showed a growing global ASIR and ASPR of PD over time, urging more effective health policies to ease its burden.

The age-specific mortality rate of parkinson's disease at all ages in Canada amounted to *** in 2023. Between 2000 and 2023, the age-specific mortality rate rose by ***, though the increase followed an uneven trajectory rather than a consistent upward trend.

Financial overview and grant giving statistics of American Parkinson Disease Association

Yearly citation counts for the publication titled "Systematic Review of the Prevalence and Incidence of Parkinson’s Disease in Asia".

Introduction: The increasing global population and aging have made Parkinson's disease (PD) a significant public health concern. Comprehensive evaluations of PD burden trends in Asian subregions and countries are lacking. This study investigated PD burden in Asia from 1990 to 2021, categorized by age, sex, and region. Methods: Data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 were analyzed to assess the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) across five Asian subregions and 34 countries/territories, using join-point regression, decomposition analysis, frontier analysis, and Bayesian models to examine changes, influencing factors, and predict future trends. Results: In 2021, the age-standardized PD incidence and prevalence in Asia were higher than the global average, particularly in East Asia (24.16 and 243.46/100,000, respectively). From 1990 to 2021, the incidence of PD in Asia rose by 198.01%, its prevalence rose by 284.35%, mortality rose by 111.27%, and DALY rose by 144.45%. Males consistently presented a greater PD burden than females did, with a growing sex gap over time. PD burden increased with age, especially among those aged 65 years and older. Population aging was the primary driver of new PD cases, and increasing etiological factors led to more patients. Inequalities in the PD burden have increased between high- and low-income areas, with low-income regions being more affected. By 2036, PD incidence is projected to increase in all subregions except the High-income Asia-Pacific region, with males experiencing a higher rate of increase. Conclusion: The PD burden in Asia has significantly increased over the past three decades, particularly in middle-aged and elderly males, middle- and low-SDI countries, and individuals already suffering from PD. The increasing incidence and aging population necessitate the reallocation of medical resources, improved chronic disease management systems, stronger public health interventions, and sustainable development efforts. Research into etiological factors, pathogenesis, early diagnosis, preventive interventions, and regional management is critical.

BackgroundThis study aims to evaluate the global, regional, and national trends in prevalence, incidence, mortality, and DALYs for early-onset Parkinson’s disease (EOPD) from 1990 to 2021.MethodsAll data from the Global Burden of Diseases (GBD) 2021 were stratified by age, sex, location, and socio-demographic index (SDI). We performed comprehensive analysis to reveal trends for EOPD, utilizing average annual percentage change (AAPC), joinpoint regression analysis, health inequality analysis, frontier analysis, and Bayesian age-period-cohort (BAPC) models.ResultsIn 2021, the global case numbers of prevalence, incidence, mortality, and DALYs for EOPD were 483872.47 (95% UI: 328861.91–682509.05), 81046.67 (95% UI: 48161.87–122328.00), 2245.68 (95% UI: 1995.24–2495.67), and 180325.32 (95% UI: 145990.30–225031.04). The age-standardized prevalence rate (ASPR), age-standardized incidence rate (ASIR), and age-standardized DALYs rate (ASDR) keep increasing from 1990 to 2021, and the age-standardized death rate (ASMR) occurred the decline trend. Male showed higher ASPR, ASIR, ASMR, and ASDR across all age groups. The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. The frontier analysis lists some countries and territories requiring urgent action to mitigate EOPD burden. Furthermore, it was anticipated that the ASPR and ASIR would consistently increase during 2021 to 2030, while the ASMR and ASDR would decrease.ConclusionEOPD demonstrated notable heterogeneity across age, gender, and geography. The increasing burden of EOPD underscored the urgent need for targeted public health strategies and policies, especially in undeveloped regions.

For current version see:

https://data.sandiegocounty.gov/Health/2021-Alzheimer-s-Disease-and-Related-Dementias/6gup-43ea

Basic Metadata

*Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.

**Blank Cells: Rates not calculated for fewer than 5 events. Rates not calculated in cases where zip code is unknown.

*API: Asian/Pacific Islander.

*AIAN: American Indian/Alaska Native.

Prepared by: County of San Diego, Health & Human Services Agency, Public Health Services, Community Health Statistics Unit, 2019.

Code Source: ICD-9CM - AHRQ HCUP CCS v2015. ICD-10CM - AHRQ HCUP CCS v2018. ICD-10 Mortality - California Department of Public Health, Group Cause of Death Codes 2013; NHCS ICD-10 2e-v1 2017.

Data Guide, Dictionary, and Codebook:

https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/CHS/Community%20Profiles/Public%20Health%20Services%20CodebookData%20GuideMetadata_10.2.19.xlsx

Splitgraph serves as an HTTP API that lets you run SQL queries directly on this data to power Web applications. For example:

See the Splitgraph documentation for more information.

Summary statistics from "Genome-wide determinants of mortality and clinical progression in Parkinson’s disease".

Background: Parkinson's disease (PD) is an increasing challenge to public health. Tracking the temporal trends of PD burden would inform health strategies.Methods: Data of PD burden was obtained from the Global Burden of Disease 2019. Trends in the incidence, prevalence, and years lived with disability (YLDs) of PD were estimated using the annual percentage change (EAPC) and age-standardized rate (ASR) from 1990 to 2019. The EAPCs were calculated with ASR through a linear regression model.Results: The overall ASR of the incidence, prevalence, and YLDs of PD increased from 1990 to 2019, and their EAPCs were 0.61 (95% confidence interval [CI]: 0.58–0.65), 0.52 (95% CI: 0.43–0.61), and 0.53 (95% CI: 0.44–0.62). The largest number of PD patients was seen in the groups aged more than 65 years, and the percentage rapidly increased in the population aged more than 80 years. Upward trends in the ASR of PD were observed in most settings over the past 30 years. Incident trends of ASR increased pronouncedly in the United States of America and Norway, in which the respective EAPCs were 2.87 (95% CI: 2.35–3.38) and 2.14 (95% CI: 2.00–2.29). Additionally, the largest increasing trends for prevalence and YLDs were seen in Norway, with the respective EAPCs of 2.63 (95% CI: 2.43–2.83) and 2.61 (95% CI: 2.41–2.80). However, decreasing trends in PD appeared in about 30 countries, particularly Italy and the Republic of Moldova.Conclusions: Increasing trends in the burden of PD were observed globally, and in most regions and countries from 1990 to 2019. Our findings suggested that the control and management of PD should be strengthened, especially when considering the aging tendency of the population.

In 2021, there were around *** deaths from Parkinson's disease among those aged 85 years and older, per 100,000 population. This graph displays the death rate from Parkinson's disease in the U.S. in 2021, by age.

Parkinson Disease Drug Market Outlook

The global Parkinson Disease Drug market size was valued at approximately USD 4.5 billion in 2023 and is projected to reach around USD 7.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of about 6.2% during the forecast period. The upward trajectory in the market is primarily driven by an increasing prevalence of Parkinson's disease worldwide, advancements in drug development, and heightened awareness about the disease and its management options. As aging populations rise and healthcare infrastructures enhance, the demand for effective treatment solutions is expected to witness substantial growth, underpinning the market's expansion.

Several factors contribute to the growth of the Parkinson Disease Drug market, with one of the key drivers being the increasing prevalence of Parkinson's disease, particularly among the aging population. Globally, as life expectancy rises, the incidence of Parkinson's disease, which primarily affects older adults, is expected to increase. This demographic shift has led to a higher demand for effective therapeutic options, spurring pharmaceutical companies to invest heavily in research and development. Moreover, the growing awareness and understanding of the disease among both the medical community and the general public have catalyzed early diagnosis and treatment, further boosting the market.

Technological advancements in drug formulation and delivery systems also play a pivotal role in shaping the market's progression. Innovations such as extended-release formulations, combination therapies, and novel drug delivery mechanisms like transdermal patches and implants have improved the efficacy and patient compliance of Parkinson's disease treatment. These advancements not only enhance the quality of life for patients but also open new avenues for pharmaceutical companies to develop specialized products that cater to specific patient needs. This trend highlights the industry's commitment to addressing the complexities of Parkinson's disease with personalized medicine approaches.

Government initiatives and healthcare policies aimed at improving neurological health care services have been instrumental in fostering market growth. Various governments and non-profit organizations have intensified their efforts to increase funding for research and development in neurodegenerative diseases, including Parkinson's. This has resulted in accelerated drug approval processes and a broader portfolio of therapeutic options entering the market. The collaboration between public health entities and private sectors has proven to be beneficial in driving innovation, ensuring a competitive market landscape, and ultimately improving patient outcomes on a global scale.

In the realm of neurodegenerative disorders, Lewy Body Dementia Drugs are gaining attention as they share some symptomatic treatments with Parkinson's disease. While Parkinson's primarily targets motor symptoms, Lewy Body Dementia presents a complex interplay of cognitive decline, visual hallucinations, and Parkinsonian symptoms. The development of drugs for Lewy Body Dementia is crucial, as they aim to address both cognitive and motor challenges, offering a comprehensive treatment approach. Pharmaceutical companies are exploring the potential of existing Parkinson's medications, such as cholinesterase inhibitors and antipsychotics, in managing Lewy Body Dementia. This cross-application not only broadens the therapeutic landscape but also underscores the need for tailored drug development strategies that consider the overlapping symptoms of these neurological conditions. As research progresses, the hope is to refine these treatments, enhancing their efficacy and safety for patients with Lewy Body Dementia.

In terms of regional outlook, North America currently dominates the Parkinson Disease Drug market, owing to a well-established healthcare infrastructure, high healthcare expenditure, and significant R&D activities in the field of neurology. The presence of major pharmaceutical companies and proactive government initiatives contribute to the region's leadership position. Europe follows closely, with a substantial geriatric population and supportive regulatory frameworks enhancing market prospects. Meanwhile, the Asia Pacific region is anticipated to witness the fastest growth rate, attributed to its large population base, increasing healthcare investments, and rising incidences of neurological disorders. Emerging markets like L

Financial overview and grant giving statistics of Michael J Fox Foundation For Parkinsons Research

Financial overview and grant giving statistics of Society to End Parkinsons Disease